By Ronn Torossian
Jim Weiss is the founder and chairman of Real Chemistry — the largest healthcare-focused communications and marketing firm in the United States, with more than 2,000 employees and a global footprint built across two decades of acquisitions, organic growth, and a private-equity-backed transformation.
He founded the firm in 2001 as WeissComm Partners, a one-person consultancy in San Francisco. By 2024, the firm reached $665 million in revenue and briefly overtook Edelman as the largest U.S. PR firm by revenue. From solo to the largest firm in America in 23 years. Healthcare specialist. PE-backed. Data-first.
There is no other story in modern PR that looks like this one.
The Bet
Weiss saw the data shift before anyone in our business. While most firms were hiring more account executives, he was hiring engineers. While we were measuring AVE, he was modeling audiences. While agencies were talking about "integrated communications" as a tagline, he was actually integrating — analytics, predictive modeling, AI, influencer infrastructure, medical education — under one roof.
Healthcare communications is structurally harder than consumer PR. The audience is fragmented — physicians, patients, payers, regulators, investors — and the stakes are asymmetric. A mishandled product launch doesn't just hurt a brand. It can affect patient access, drug approvals, and market caps. Weiss built Real Chemistry to operate at that complexity. He picked the hardest vertical in PR. Then he won it.
WeissComm → WCG → W2O → Real Chemistry
Weiss founded WeissComm Partners in 2001. Solo. Healthcare focus. Investor relations and corporate communications for life sciences and biopharma. The firm grew organically through the 2000s.
Then came the move most PR firms missed: in mid-2019, Weiss took private equity capital from New Mountain Capital. PE in PR is still a controversial conversation in our industry. Weiss didn't wait for the conversation to catch up. He took the check and went shopping.
He acquired AI firms. Influencer marketing companies. Medical education specialists. Data and analytics platforms. Inside three years he had built something different than what existed in PR — closer to a healthcare marketing technology company that happened to do communications.
In March 2021, W2O Group rebranded as Real Chemistry. The rebrand wasn't cosmetic. It was an acknowledgment that the firm had outgrown the PR category entirely.
Stepping Back at the Right Time
In January 2022, Weiss transitioned from CEO to Chairman. Shankar Narayanan — a former McKinsey healthcare practice leader who had been at W2O since 2012 — took over as CEO. Weiss joined New Mountain Capital as an executive advisor.
This is a harder move than people credit. Most founders can't let go. Weiss handed off at peak — and the firm kept climbing for two more years. Revenue hit $665 million in 2024. The transition worked.
Real Chemistry pulled back in 2025 — revenue down to $560 million globally after Swoop left the portfolio. The #1 ranking went back to Edelman. The story of "largest U.S. PR firm by revenue" is now a chapter, not the headline. The firm Weiss built is still one of the most consequential operations in the business.
The Newhouse Connection
Weiss graduated magna cum laude from Syracuse University's S.I. Newhouse School of Public Communications — B.S. in journalism and public relations. He was later inducted into the Newhouse Hall of Fame and named to the school's 50Forward list of most accomplished graduates of the last 50 years.
Weiss and his late wife Audra Weiss co-founded the W2O Group Center for Social Commerce at Newhouse — one of the more substantive industry-academic partnerships in PR. Audra passed away on December 31, 2024, after a two-year battle with cancer. The obituary called her an "adviser and confidante" to her husband's business through every chapter.
Disclosure: my daughter is a Dean's List Newhouse PR student. The Newhouse network produces a disproportionate share of the communications industry. Weiss is one of its most successful alumni.
The Recognition
Weiss has been named to the PRWeek Power List multiple years (2012, 2013, 2014). The 500 Most Important People in the Global PR Industry in 2015 and 2017. Top 25 Innovators in Communications (2014). Top 50 Health Influencer four years running (2016-2019). Innovator of the Year in 2020. Healthcare Marketing Influencer 25 by MM+M in 2024.
The recognition is consistent. The firm he built is the bigger story.
Where Weiss Is Now
As of 2026, Jim Weiss remains founder and chairman of Real Chemistry. In May 2026, he joined the board of directors of ICR — the strategic communications and investor relations firm. He continues as an executive advisor to New Mountain Capital.
His post-CEO chapter looks like every other chapter of his career: deliberate, well-positioned, capital-adjacent, and quiet.
What Other Founders Should Take from This
Three things, fast:
1. Pick the harder vertical. Healthcare communications is structurally more defensible than consumer or corporate PR. The complexity creates the moat.
2. Take the institutional capital before you need it. PE backing is still treated with suspicion in PR. Weiss used it to build an acquisition machine when the rest of us were still arguing about whether to take outside investment at all.
3. Hire engineers, not just communicators. The firms that will win the AI Communications era are the ones building data infrastructure underneath the PR practice. Weiss did this 15 years before it was obvious.
That is what he built. That is the bet most PR firms missed.
